Boehringer Aims To Block GSK's Triple COPD Inhaler, Citing Combo Rule
Executive Summary
GSK's triple COPD combo needs Phase III trial using comparators with same active ingredients and applying factorial design, BI contends in citizen petition to US FDA.
You may also be interested in...
Expanded IMPACT For GSK Respiratory Business From New Trelegy Data
Headline data from GlaxoSmithKline's IMPACT study comparing its new triple therapy Trelegy Ellipta with the company's dual therapies Breo/Relvar Ellipta and Anoro Ellipta support the product's ability to reduce exacerbations in more severe COPD. However, the benefit of IMPACT in expanding GSK's respiratory sales may be limited given pricing pressures and the make-up of GSK's current portfolio.
Trelegy Approval Boosts GSK's US Respiratory Business But Pressure Remains
With the FDA approval of Trelegy Ellipta, GlaxoSmithKline will enjoy first-to-market status with a LABA/LAMA/ICS triple combination therapy to treat COPD in the US. However, it faces the challenge of convincing payers.
New Treatments For Psoriasis, Ovarian Cancer And MS Seeking CHMP Thumbs Up This Week
Fourteen medicines that are in the final stages of the evaluation process at the European Medicines Agency should find out this week whether they will be approved for marketing across the EU.